[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
브릭 굿즈 홍보
스폰서배너광고 안내  배너1 배너2 배너3 배너4
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
정경해
정경해 (Kyung Hae Jung) 저자 이메일 보기
울산대학교 의과대학, 서울아산병원
 
조회 79  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
열기 Authors and Affiliations

Abstract

Background
Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Methods
This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0–2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks). Randomisation was stratified by previous chemotherapy for metastatic breast cancer and visceral metastasis. The primary endpoint was progression-free survival. All analyses were done in a modified intention-to-treat population that excluded patients who did not receive study medication. This study is registered with ClinicalTrials.gov, NCT02592746, and is ongoing for follow-up of overall survival.

Findings
Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184 were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92). Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the capecitabine group were included in the modified intention-to-treat analyses. 46 (50%) of 92 patients in the palbociclib plus endocrine therapy group and 45 (51%) of 92 in the capecitabine group were treatment naive for metastatic breast cancer. During a median follow-up of 17 months (IQR 9–22), median progression-free survival was 20·1 months (95% CI 14·2–21·8) in the palbociclib plus endocrine therapy group versus 14·4 months (12·1–17·0) in the capecitabine group (hazard ratio 0·659 [95% CI 0·437–0·994], one-sided log-rank p=0·0235). Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 vs 14 [16%] of 86 patients). 2 (2%) patients in the palbociclib plus endocrine therapy group and 15 (17%) patients in the capecitabine group had treatment-related serious adverse events. No treatment-related deaths occurred.

Interpretation
Exemestane plus palbociclib with ovarian function suppression showed clinical benefit compared with capecitabine in terms of improved progression-free survival in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus exemestane with ovarian suppression is an active treatment option in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with tamoxifen.

Funding
Pfizer, Shinpoong, and Daewoong Korea and Takeda.

논문정보
- 형식: Research article
- 게재일: 2019년 10월 (BRIC 등록일 2019-10-25)
- 연구진: 국내연구진태극기
- 분야: Cancer Biology/Oncology
N-말단 법칙/N-데그론 기전으로 매개되는 소포체 자가포식 [Mol. Cell]
지창훈
발표: 지창훈 (서울대학교 의과대학)
일자: 2019년 11월 14일 (목) 오후 03시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
한국기초과학지원연구원
관련링크
정경해 님 전체논문보기 >
관련인물
김선영 (울산대학교 의과대학, 서울아...)
김태원 (울산대학교 의과대학, 서울아...)
박연희 (성균관대학교 의과대학, 삼성...)
임석아 (서울대학교 의과대학)
임영혁 (성균관대학교 의과대학, 삼성...)
홍용상 (울산대학교 의과대학, 서울아...)
관련분야 논문보기
Cancer Biology/Oncology

외부링크
Google (by Kyung Hae Jung)
Pubmed (by Kyung Hae Jung)
프리미엄 Bio일정 Bio일정 프리미엄 안내
2020년도 신약개발지원센터 기반기술구축사업 ‘최적화 기술지원’ 분야 신규과제 공고
[11.12~11.13 재직자무료교육] 비임상시험 이해
[11.12~11.13 재직자무료교육] 비임상시험 이해
날짜: 2019.11.12~13
장소: 청주시 흥덕구 오송생명1로 194-41 기업연구1관 충북산학융합본부
근거중심의료 논문완성과정 체계적 고찰/메타분석 워크숍(중급)
근거중심의료 논문완성과정 체계적 고찰/메타분석 워크숍(중급)
초록접수: ~2019.11.23
날짜: 2019.11.30
장소: 충북대학교 의과대학 임상연구동(E7-2동) 101호_
[고용부 재직자 무료과정] GMP 중급과정
[고용부 재직자 무료과정] GMP 중급과정
날짜: 2019.11.20~22
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실1
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
머크